Compare BEAM & HUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEAM | HUN |
|---|---|---|
| Founded | 2017 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | 2019 | 2004 |
| Metric | BEAM | HUN |
|---|---|---|
| Price | $32.61 | $14.24 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 11 |
| Target Price | ★ $50.75 | $12.09 |
| AVG Volume (30 Days) | 1.7M | ★ 4.3M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.64% |
| EPS Growth | ★ 82.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $24,000.00 | ★ $5,683,000,000.00 |
| Revenue This Year | N/A | $3.08 |
| Revenue Next Year | $33.77 | $5.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 33.33 | N/A |
| 52 Week Low | $15.60 | $7.30 |
| 52 Week High | $36.44 | $15.90 |
| Indicator | BEAM | HUN |
|---|---|---|
| Relative Strength Index (RSI) | 57.71 | 48.72 |
| Support Level | $26.23 | $13.13 |
| Resistance Level | $34.29 | $15.60 |
| Average True Range (ATR) | 1.88 | 0.62 |
| MACD | 0.13 | -0.03 |
| Stochastic Oscillator | 82.27 | 47.64 |
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Huntsman Corp is a USA-based manufacturer of differentiated organic chemical products. The product portfolio of the company comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, and others. Its operating segments are Polyurethanes, Performance Products, and Advanced Materials. The company derives the majority of its revenue from the Polyurethanes segment, which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States & Canada, Europe, Asia-Pacific, and the Rest of the world.